2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
This program provides coverage of the 2018 ASCO annual meeting with summary slidesets and expert analyses of key results in gastrointestinal cancers, gynecologic cancers, skin cancer, cancer immunotherapy, genitourinary cancers, hematologic malignancies, breast cancer, and lung cancer.

Genitourinary Cancers

Capsule Summary Slidesets

Pembrolizumab active in the first-line setting for patients with advanced ccRCC with no unexpected toxicities.

Released: June 6, 2018

This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.

Released: June 12, 2018

Enfortumab vedotin, an investigational antibody-drug conjugate, appears well tolerated in this phase I study with an ORR of 41% in previously treated patients with mUC.

Released: June 8, 2018

Neoadjuvant therapy with atezolizumab yielded a pCR of 29% in cisplatin-ineligible patients with operable bladder cancer.

Released: June 7, 2018

Neoadjuvant pembrolizumab associated with a pathologic CR rate of 39.5% and no surgical delay in MIBC patients scheduled for radical cystectomy.

Released: June 12, 2018

All assessed patient-reported outcomes favored first-line therapy with atezolizumab + bevacizumab over sunitinib in mRCC.

Released: June 5, 2018

Lenvatinib plus pembrolizumab associated with an ORR of 63% at 24 weeks and tumor size reduction in 29/30 patients.

Released: June 7, 2018

Combination of a PARP inhibitor plus ADT increases radiologic PFS in patients with docetaxel-treated mCRPC.

Released: June 3, 2018

In this phase II study, pembrolizumab showed antitumor activity in a subset of previously treated patients with metastatic CRPC regardless of PD-L1 expression status.

Released: June 8, 2018

Final analysis showed survival with sunitinib alone not inferior to nephrectomy followed by sunitinib.

Released: June 6, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue